GSK’s new shingles vaccine may win nod over Merck’s Zostavax
October is shaping up to be a momentous month for GlaxoSmithKline’s new shingles vaccine, Shingrix.
The Food and Drug Administration may approve the vaccine for the U.S. market by the end of this week, based on a strong recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee. In mid-September, this group voted unanimously that there is enough evidence to conclude Shingrix is both safe and effective in people 50 and older.
